<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665947</url>
  </required_header>
  <id_info>
    <org_study_id>1667622</org_study_id>
    <nct_id>NCT04665947</nct_id>
  </id_info>
  <brief_title>First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer</brief_title>
  <official_title>First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga&#xD;
      DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or&#xD;
      metastatic pancreatic adenocarcinoma (PDAC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, first-in-human study to evaluate the safety and efficacy of the [68Ga]Ga&#xD;
      DOTA-5G /[177Lu]Lu DOTA-ABM-5G theranostic pair in patients with locally advanced or&#xD;
      metastatic pancreatic ductal adenocarcinoma (PDAC). PET imaging using [68Ga]Ga DOTA-5G will&#xD;
      be used to diagnose patients who are eligible for the [177Lu]Lu DOTA-ABM-5G. The overall&#xD;
      purpose of this study is to identify the dose limiting toxicity (DLT) and recommended phase 2&#xD;
      dose (RP2D) of [177Lu]Lu DOTA-ABM-5G. A 3+3 study design in is proposed to identify the RP2D&#xD;
      of [177Lu]Lu DOTA-ABM-5G. An expansion group will receive the RP2D in order to obtain initial&#xD;
      estimates of response and additional information on safety of [177Lu]Lu DOTA-ABM-5G.&#xD;
&#xD;
      The hypotheses of this phase I study are that a) [68Ga]Ga DOTA-5G will detect lesions in&#xD;
      patients with locally advanced or metastatic pancreas cancer b) the theranostic pair [68Ga]Ga&#xD;
      DOTA-5G/ [177Lu]Lu DOTA-ABM-5G will be safe and well tolerated c) we will be able to identify&#xD;
      a Recommended Phase 2 Dose (RP2D) for [177Lu]Lu DOTA-ABM-5G therapy to be used in subsequent&#xD;
      Phase II trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a first-in-human 3 + 3 study design to identify dose limiting toxicity and recommended phase 2 dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[68Ga]Ga DOTA-5G PET/CT imaging</measure>
    <time_frame>2 hours from time of injection</time_frame>
    <description>Assessment of [68Ga]Ga DOTA-5G PET/CT imaging to detect lesions in patients with locally advanced or metastatic pancreatic cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[177Lu]Lu DOTA-ABM-5G dose escalation therapy</measure>
    <time_frame>30 days from time of injection</time_frame>
    <description>Frequency of dose-limiting toxicities (DLT) of [177Lu]Lu DOTA-ABM-5G at escalating dose levels of [177Lu]Lu DOTA-ABM-5G</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G</measure>
    <time_frame>7-14 days from time of injection</time_frame>
    <description>Assessment of organ dosimetry of [177Lu]Lu DOTA-ABM-5G using SPECT/CT imaging at various timepoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Locally Advanced Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>[177Lu]Lu DOTA-ABM-5G dose escalation therapy study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of [68Ga]Ga DOTA-5G PET/CT will be offered therapy. Escalating doses of 25-200 mCi of [177Lu]Lu DOTA-ABM-5G will be administered in a traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recommended Phase 2 dose [177Lu]Lu DOTA-ABM-5G therapy study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be undergo [68Ga]Ga DOTA-5G PET/CT scans to confirm eligibility for the [177Lu]Lu DOTA-ABM-5G therapy.10 patients will be enrolled in the dose expansion cohort and recieve the highest dose achieved in the [177Lu]Lu DOTA-ABM-5G dose escalation therapy study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.</intervention_name>
    <description>PET imaging using [68Ga]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the [177Lu]Lu DOTA-ABM-5G.</description>
    <arm_group_label>Recommended Phase 2 dose [177Lu]Lu DOTA-ABM-5G therapy study</arm_group_label>
    <arm_group_label>[177Lu]Lu DOTA-ABM-5G dose escalation therapy study</arm_group_label>
    <other_name>[68Ga]Ga DOTA-5G</other_name>
    <other_name>[177Lu]Lu DOTA-ABM-5G</other_name>
    <other_name>[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G theranostic pair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        [68Ga]Ga DOTA-5G PET/CT Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
          2. Age 18 or more years&#xD;
&#xD;
          3. Confirmed presence of locally advanced, unresectable or metastatic pancreatic&#xD;
             adenocarcinoma (other pancreatic malignant histologies are excluded) with measurable&#xD;
             disease per RECIST (version 1.1) (i.e. at least 1 lesion &gt; 1 cm or lymph node &gt; 1.5 cm&#xD;
             in short axis)&#xD;
&#xD;
          4. Participant must have documented tumor progression during or following at least one&#xD;
             prior systemic regimen as established by CT or MRI scan within 28 days of enrollment&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group Performance Status ≤ 2&#xD;
&#xD;
          6. Participant must have completed prior chemotherapy at least 2 weeks (washout period)&#xD;
             prior to [68Ga]Ga DOTA-5G PET scan. Any clinically significant toxicity (with the&#xD;
             exceptions of hair loss and sensory neuropathy) related to prior therapy resolved to&#xD;
             Grade 1 or baseline.&#xD;
&#xD;
          7. Hematologic parameters defined as:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1000 cells/mm3&#xD;
&#xD;
               2. Platelet count ≥ 100,000/mm3&#xD;
&#xD;
               3. Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          8. Blood chemistry levels defined as:&#xD;
&#xD;
               1. AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN)&#xD;
&#xD;
               2. Total bilirubin ≤ 2 times ULN&#xD;
&#xD;
               3. Creatinine ≤ 2 times ULN&#xD;
&#xD;
          9. Anticipated life expectancy ≥ 3 months&#xD;
&#xD;
         10. Able to remain motionless for up to 30-60 minutes per scan&#xD;
&#xD;
        [177Lu]Lu DOTA-ABM-5G therapy Inclusion Criteria:&#xD;
&#xD;
          1. Completion of entry into [68Ga]Ga DOTA-5G PET study and completion of scan&#xD;
&#xD;
          2. The presence of at least one measurable disease by [68Ga]Ga DOTA-5G PET/CT&#xD;
             (SUVmax&gt;2-fold above normal lung or liver)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G therapy Exclusion Criteria:&#xD;
&#xD;
               1. Participant on any chemical anticoagulant including antiplatelet agents&#xD;
                  (excluding ASA)&#xD;
&#xD;
               2. Participants with Class 3 or 4 NYHA Congestive Heart Failure&#xD;
&#xD;
               3. Clinically significant bleeding within two weeks prior to trial entry (e.g.&#xD;
                  gastrointestinal bleeding, intracranial bleeding)&#xD;
&#xD;
               4. Pregnant or lactating women&#xD;
&#xD;
               5. Major surgery, defined as any surgical procedure that involves general anesthesia&#xD;
                  and a significant incision (i.e. larger than what is required for placement of a&#xD;
                  central venous access, percutaneous feeding tube, or biopsy) within 28 days prior&#xD;
                  to study day 1 or anticipated surgery within the subsequent 6 weeks&#xD;
&#xD;
               6. Has an additional active malignancy requiring therapy within the past 2 years&#xD;
&#xD;
               7. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic&#xD;
                  therapy&#xD;
&#xD;
               8. Psychiatric illness/social situations that would interfere with compliance with&#xD;
                  study requirements&#xD;
&#xD;
               9. Previous radiation therapy for the treatment of advanced or metastatic disease&#xD;
&#xD;
              10. Cannot undergo PET/CT scanning because of weight limits (350 lbs)&#xD;
&#xD;
              11. INR&gt;1.2; PTT&gt;5 seconds above UNL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie L Sutcliffe</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie L Sutcliffe</last_name>
    <phone>916-734-5536</phone>
    <email>jlsutcliffe@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie L Sutcliffe</last_name>
      <phone>916-734-5536</phone>
      <email>jlsutcliffe@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Sutcliffe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Julie L. Sutcliffe, Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>integrin</keyword>
  <keyword>metastatic pancreatic cancer</keyword>
  <keyword>PET</keyword>
  <keyword>theranostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

